Etonogestrel implant - Merck & Co

Drug Profile

Etonogestrel implant - Merck & Co

Alternative Names: 3-Keto-desogestrel; 3-Keto-DOG; 3-Oxodesogestrel; Implanon; Implanon NXT; Nexplanon; ORG-3236

Latest Information Update: 07 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Pharmaco (NZ); Schering-Plough
  • Class Hormonal contraceptives; Norpregnanes; Phenanthrenes; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Mar 2018 Merck initiates enrolment in a phase I trial for Pregnancy (Prevention) in USA (Intradermal) (NCT03335163)
  • 09 Nov 2011 A new formulation of the etonogestrel implant has been launched as Nexplanon® for Contraception in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top